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Background: Few studies from the general population have investigated the role of anxiety in
reporting dyspnoea. We examined the independent and combined association of lung function
and anxiety symptoms with the prevalence of dyspnoea in different situations.
Methods: The study included 5627 women and 5066 men who participated in the Lung study of
the Nord-Trøndelag Health Study second survey in 1995e97. In a cross-sectional design we used
logistic regression to calculate adjusted odds ratios (ORs) for reporting dyspnoea associated
with levels of percent predicted FEV1 (ppFEV1) and anxiety (Hospital Anxiety and Depression
Scale).
Results: Overall, there was a linear inverse association between ppFEV1 and dyspnoea (all
Ptrend < 0.001), and a positive association between anxiety symptoms and dyspnoea (all
Ptrend < 0.001). In combined analysis, using people with ppFEV1 100 without anxiety as refer-
ence, the OR (95% confidence interval) for reporting dyspnoea when walking on flat ground was
6.23 (3.45e11.28) in women with ppFEV1 <80 without anxiety and 15.14 (7.13e32.12) in
women with ppFEV1 <80 with anxiety. The corresponding ORs among men were 5.75 (2.23
e14.18) and 15.19 (4.74e48.64), respectively. Similar patterns were seen for dyspnoea when
sitting still and woken at night by dyspnoea.
Conclusion: Impaired lung function and anxiety symptoms were independently associated with
reporting dyspnoea. Within lung function levels, reporting dyspnoea was more common among3 59 88 05, þ47 95 22 88 68 (Mobile); fax: þ47 73 59 75 77.
u.no (L. Leivseth).
2 Elsevier Ltd. All rights reserved.
Lung function, anxiety, and dyspnoea 1149people with anxiety symptoms than among people without. This suggests that, in addition to its
relation to reduced lung function, the subjective experience of breathing discomfort may also
influence or be influenced by anxiety.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
The prevalence and burden of obstructive lung diseases are
increasing.1,2 Lung function measurements, in particular
forced expiratory volume in one second (FEV1), are impor-
tant in the diagnosis of asthma and chronic obstructive
pulmonary disease (COPD) and in the physiological staging
of COPD.1,2 However, dyspnoea and anxiety, which are
common symptoms among people with obstructive lung
diseases,2e4 have been found to explain more of the vari-
ation in subjective health status of people with COPD than
physiological variables like FEV1.
5 Studies from the general
population suggest that dyspnoea has a stronger association
with health-related quality of life than lung function,6,7
whereas FEV1 has been reported to correlate weakly with
dyspnoea in people with COPD.8
Dyspnoea is a subjective experience of breathing
discomfort9 and a prominent symptom of asthma and
COPD.1,2 However, dyspnoea is also a symptom of anxiety,
especially in people with panic disorder or hyperventilation
syndrome.3 Some studies have found associations between
anxiety and dyspnoea independent of FEV1,
10e12 also in
people with normal lung function.13 This indicates that
anxiety may explain some of the variation in reported
dyspnoea that is not explained by FEV1.
Previous studies linking lung function, anxiety, and
dyspnoea are mainly limited to people with specific diag-
noses like asthma and COPD.14,15 However, a few studies
from the general population have found associations
between psychological and respiratory symptoms.11,13,15,16
The aim of this large epidemiologic study from a general
population was to examine the independent and combined
association of objectively measured lung function and
reported anxiety symptoms with the prevalence of dysp-
noea in different situations.Methods
Study population
All residents of Nord-Trøndelag County in Norway aged 20
years or more were invited to the second survey of the
large population-based Nord-Trøndelag Health Study
(HUNT 2) between 1995 and 1997. HUNT 2 has been
described in detail elsewhere.17 Among the 65,215
participants who attended the primary screening (69.5%
of those invited), about 20% were invited to the Lung
study due to limited capacity for spirometric measure-
ments at the screening station. The Lung study consisted
of a 5% random sample and a symptom sample.18,19 The
symptom sample included subjects reporting attacks of
wheezing or breathlessness during the last 12 months,
having ever had asthma, and/or having ever used asthmamedication, and who were not included in the random
sample. A flow chart of inclusion and exclusion in the Lung
study is presented in Fig. 1. Among the 13,518 individuals
invited to perform spirometry, 10,848 (80.2%) had
acceptable spirometry at the screening station. However,
further quality assurance revealed 29 unacceptable
spirometric measurements, and these were excluded from
the analyses. In addition, 126 subjects were excluded due
to misclassification. The analyses included the remaining
10,693 subjects, and these were weighted to represent
53,196 subjects from the general population of Nord-
Trøndelag County.
Study variables
All participants in HUNT 2 filled in a general questionnaire
on life style factors, complaints, and diseases.19 Demo-
graphic data were recorded. Participants in the Lung study
completed an additional lung specific questionnaire and an
interview,19 and performed flow volume spirometry.
Dyspnoea
We used measures of dyspnoea during three different
situations; a) dyspnoea when walking on flat ground, b)
dyspnoea when sitting still, and c) woken at night by
dyspnoea. The lung-specific questionnaire included four
questions about dyspnoea at various activities with “yes” or
“no” as possible answers: Q1 “Do you become more short of
breath than people your age when walking uphill?”, Q2 “Do
you become short of breath when you climb two flights of
stairs at normal pace?”, Q3 “Do you become short of breath
when walking on flat ground at a normal pace?”, and Q4
“Are you short of breath when sitting still?” These questions
were included in the Norwegian respiratory question-
naire20,21 and have been used in Norwegian epidemiologic
studies.17,21 The four questions were combined to a scale
(25.7% missing), and cut-off was set at “yes” for Q3
(dyspnoea when walking on flat ground) or Q4 (dyspnoea
when sitting still) which approximates dyspnoea grades 2
and 4, respectively, according to the modified British
Medical Research Council dyspnoea scale.22 In the interview
the participants were asked “Have you woken at night
because you were short of breath in the last 12 months?”
Those answering “yes” were classified as woken at night by
dyspnoea (0.47% missing).
Lung function
Flow volume spirometry was recorded according to the
1994 ATS recommendations23 using three pneumotacho-
graphs (MasterScope Spirometer version 4.15, Erich Jaeger
GmbH, Wuerzburg, Germany).19 The spirometric measure-
ments and quality control in the Lung study are described in
detail elsewhere.18 Pre-bronchodilator forced vital
capacity (FVC) and FEV1 were obtained, and local
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Figure 1 Flow chart of inclusion and exclusion in the Lung study.
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defined in two ways; first percent predicted FEV1 (ppFEV1)
was categorised as 100.0, 80.0e99.9, 50.0e79.9, and
<50.0; then COPD was defined as FEV1/FVC <70% and
categorised according to modified Global Initiative for
Chronic Obstructive Lung Disease (GOLD) criteria2 as stage
1 (ppFEV1  80), stage 2 (50  ppFEV1 < 80), and stage 3 or
4 (ppFEV1 < 50). Normal was defined as FEV1/FVC 70% and
percent predicted FVC 80, and those with possible
restriction (FEV1/FVC  70% and percent predicted FVC
<80) were excluded from these analyses. In the analysis of
the combined association of lung function and anxiety with
dyspnoea, the latter two groups of lung function were
collapsed to increase statistical power.
Anxiety
A Norwegian translation of the Hospital Anxiety and
Depression Scale (HADS) was used to measure anxiety.24
Although the HADS questionnaire was originally developed
to measure anxiety and depression in non-psychiatric
patients treated in hospitals, it has also been reported to
be valid when used in the general population.25,26 The HADS
consists of 14 questions of which seven measure symptoms
of anxiety and seven measure symptoms of depression
during the past week. Each question is given a score of 0e3,
and the total score for each subscale ranges from 0 to 21. Ascore of 0e7 indicates normal state, 8e10 borderline state,
and 11e21 anxiety state.26 Psychometric properties of the
HADS have been thoroughly tested.25,27 When one or two
answers were missing, the total score was extrapolated by
multiplying the sum by 7/6 or 7/5, respectively. In the main
analyses anxiety was categorized into three groups; no
anxiety (HADS 0e7), borderline (HADS 8e10), and anxiety
(HADS 11e21); whereas in the analysis of the combined
association of lung function and anxiety, the latter two
groups were collapsed into one anxiety symptoms category
(HADS 8e21) to increase statistical power. When anxiety
was entered as a possible confounder to the association
between lung function and dyspnoea, people with missing
data on three or more HADS questions (5.92%) were
included in a separate category labelled unknown.Statistical analyses
To enhance the generalizability of our results the regression
analyses were weighted to reflect the distribution in the
general population. We used an inverse probability weight28
according to whether the participants were recruited
through the symptom or the random sample. A weight of one
was assigned to all included through the symptomsample and
those in the random sample who fulfilled the inclusion
Lung function, anxiety, and dyspnoea 1151criteria for the symptom sample. The remaining participants
of the random sample were assigned a weight of 20 (as 20 is
the inverse of 5%). We also performed sensitivity analyses
including subjects from the random sample only.
All analyses were conducted sex specific.29 Logistic
regression was used to compute adjusted odds ratios (ORs)
with 95% confidence intervals (CIs) for three separate
outcomes; a) dyspnoea when walking on flat ground, b)
dyspnoea when sitting still, and c) woken at night by
dyspnoea. First, we estimated the adjusted ORs for the
three outcomes within levels of lung function (ppFEV1 or
COPD stages) using the highest lung function level as
reference. Trend tests across ppFEV1 levels were conducted
using the sex specific median value within each ppFEV1
level as an ordinal variable in the regression model. Trend
tests across COPD stages were conducted using the stages
as an ordinal variable. Second, we calculated ORs for the
three dyspnoea outcomes associated with anxiety using no
anxiety as reference. Linear trend across the anxiety
categories was assessed using the categories as an ordinal
variable. Third, joint categories of lung function (ppFEV1 or
COPD stages) and anxiety were used to estimate the
combined association to the three dyspnoea measures using
the highest category of lung function without anxiety as the
reference category.
All estimated associations were adjusted for potential
confounding with age (<40.0, 40.0e49.9, ., 80.0), body
mass index (BMI) (<18.5, 18.5e24.9, 25.0e29.9, 30.0 kg/
m2), smoking history (never smoker, former smoker and
<15 pack-years, former smoker and 15 pack-years,
current smoker and <15 pack-years, current smoker and
15 pack-years, unknown [5.26%]), educational level (<10,
10e12, 13 years, unknown [5.63%]), and physical activity
(inactive, light activity <1 h per week, light activity 1e2 h
per week, light activity 3 h per week, only vigorous
activity, unknown [11.76%]). Additionally, lung function and
anxiety were mutually adjusted when assessing their
independent association with the dyspnoea measures. AgeTable 1 Baseline characteristics of the weighted sample in th
n Z 53,196).
Participants Age [years] Body mass
index
[kg/m2]
Education
13 year
ppFEV1
a n (%)b Mean (SD) Mean (SD) n (%
Women
100 12,365 (43.0) 49.5 (16.8) 26.0 (3.8) 2666 (22
80e99 12,665 (44.0) 48.4 (15.8) 26.4 (4.7) 2439 (20
50e79 3481 (12.1) 56.0 (15.6) 26.9 (5.3) 345 (11
<50 277 (1.0) 60.7 (13.9) 24.6 (5.7) 4 (1
Men
100 9075 (37.2) 48.3 (15.2) 26.2 (3.1) 1996 (23
80e99 11,634 (47.7) 49.5 (15.7) 26.6 (3.6) 2024 (18
50e79 3317 (13.6) 58.8 (15.7) 26.5 (3.6) 371 (12
<50 382 (1.6) 69.9 (9.4) 25.8 (3.9) 13 (3
a ppFEV1 denotes percent predicted forced expiratory volume in on
b Percent of total.
c Percent within ppFEV1 level, missing excluded.
d Anxiety or depression symptoms defined as score 8e21 on the Hosand BMI were entered as categorical variables in the
regression models to avoid possible residual confounding
due to non-linear associations. In separate analyses we
additionally adjusted for depression (HADS 0e7, 8e10,
11e21, unknown) when studying the association between
anxiety and dyspnoea.
All statistical tests were two-sided using Stata for
Windows (StataCorp. 2009. Stata Statistical Software:
Release 11. College Station, TX: StataCorp LP).
Ethics
The study was approved by the Regional Committee for
Medical Research Ethics (reference 4.2008.59). The
Norwegian Data Inspectorate licensed the research register
(reference 06/00104-39/CGN).
Results
Baseline characteristics
In general, people with low levels of ppFEV1 were charac-
terised by older age, less education, more inactivity, and
a higher proportion was ever smokers (Table 1). Moreover,
mean BMI was lowest among those with ppFEV1 <50. The
prevalence of anxiety and depression symptoms increased
with lower ppFEV1 among women. Baseline characteristics
of the subjects among the random, symptom, and weighted
samples are presented in Table S1 in the online supple-
ment. The prevalence and mean of key variables did
not differ much between the random and the weighted
sample.
Lung function in association with dyspnoea
The adjusted ORs for reporting dyspnoea when walking on
flat ground, dyspnoea when sitting still, and woken at nighte Lung study according to levels of lung function (weighted
s
Ever
smokers
Inactive Anxiety
symptomsd
Depression
symptomsd
)c n (%)c n (%)c n (%)c n (%)c
.5) 4917 (42.4) 630 (5.7) 1868 (16.0) 1023 (8.6)
.3) 6226 (51.9) 760 (6.8) 2231 (18.6) 1413 (11.6)
.3) 2225 (68.8) 331 (11.7) 680 (21.0) 465 (13.9)
.7) 191 (72.1) 74 (38.9) 78 (30.8) 63 (24.2)
.1) 4272 (50.3) 367 (4.4) 840 (9.8) 866 (9.9)
.5) 6866 (64.5) 918 (8.7) 1196 (11.0) 1187 (10.8)
.1) 2501 (77.9) 306 (10.8) 331 (10.6) 321 (10.2)
.8) 350 (95.1) 57 (19.4) 31 (8.9) 60 (16.8)
e second.
pital Anxiety and Depression Scale.
Table 2 Weighted prevalence and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) for reporting dyspnoea when walking on flat ground, dyspnoea when sitting
still, and woken at night by dyspnoea according to levels of lung function.
Women Men
Dyspnoea Dyspnoea
ppFEV1
a Total n (%)b ORc ORd (95% CI)d Ptrend
d Total n (%)b ORc ORd (95% CI)d Ptrend
d
Dyspnoea when walking on flat ground Dyspnoea when walking on flat ground
100 9138 166 (1.8) 1.00 1.00 Reference 6695 129 (1.9) 1.00 1.00 Reference
80e99 9023 506 (5.6) 3.38 2.80 (1.61 to 4.87) 8311 231 (2.8) 1.39 1.13 (0.52 to 2.44)
50e79 2691 301 (11.5) 6.75 5.24 (3.04 to 9.03) 2405 274 (11.4) 5.11 4.00 (1.67 to 9.59)
<50 230 108 (47.0) 43.60 42.98 (17.59 to 105.03) <0.001 303 164 (54.1) 37.79 38.27 (13.99 to 104.68) <0.001
Dyspnoea when sitting still Dyspnoea when sitting still
100 9138 62 (0.7) 1.00 1.00 Reference 6695 53 (0.8) 1.00 1.00 Reference
80e99 9023 154 (1.7) 2.57 2.23 (0.96 to 5.17) 8311 104 (1.3) 1.54 1.20 (0.52 to 2.80)
50e79 2691 98 (3.7) 6.17 3.75 (1.44 to 9.77) 2405 92 (3.8) 4.37 2.92 (1.22 to 7.00)
<50 230 15 (6.5) 10.74 10.41 (3.36 to 32.30) <0.001 303 27 (8.9) 10.06 7.33 (2.41 to 22.29) <0.001
Woken at night by dyspnoea Woken at night by dyspnoea
100 12,301 305 (2.5) 1.00 1.00 Reference 8972 204 (2.3) 1.00 1.00 Reference
80e99 12,593 566 (4.5) 1.90 1.73 (1.18 to 2.52) 11,626 444 (3.8) 1.73 1.40 (0.82 to 2.38)
50e79 3477 290 (8.3) 3.66 3.36 (2.18 to 5.17) 3313 298 (9.0) 4.31 4.44 (2.58 to 7.65)
<50 275 84 (30.5) 17.00 18.27 (8.63 to 38.67) <0.001 380 113 (29.7) 19.48 19.14 (9.29 to 39.47) <0.001
a ppFEV1 denotes percent predicted forced expiratory volume in one second.
b Percentage reporting symptom within each ppFEV1 level.
c Adjusted for age (<40.0, 40.0-49.9,., 80.0 years).
d Adjusted for age (<40.0, 40.0-49.9,., 80.0 years), anxiety (no anxiety, borderline, anxiety, unknown), body mass index (<18.5, 18.5-24.9, 25.0-29.9, 30.0 kg/m2), smoking history
(never smoker, former smoker and <15 pack-years, former smoker and 15 pack-years, current smoker and <15 pack-years, current smoker and 15 pack-years, unknown), educational
level (<10, 10-12, 13 years, unknown), and physical activity (inactive, light activity <1 hours per week, light activity 1-2 hours per week, light activity 3 hours per week, only vigorous
activity, unknown).
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Lung function, anxiety, and dyspnoea 1153by dyspnoea increased with lower ppFEV1 (Table 2) or higher
COPD stage (Table S2) (all Ptrend < 0.002). Women with
ppFEV1 50e79 had an OR of 5.24 (95% CI 3.04e9.03) for
dyspnoea when walking on flat ground compared to women
with ppFEV1 100, whereas the corresponding association
among men was 4.00 (95% CI 1.67e9.59) (Table 2).
Anxiety in association with dyspnoea
The adjusted ORs for reporting dyspnoea when walking on
flat ground, dyspnoea when sitting still, and woken at night
by dyspnoea increased with increasing anxiety symptoms
(all Ptrend < 0.001) (Table 3). Women with anxiety (HADS
11e21) had an OR of 3.39 (95% CI 1.95e5.88) for dyspnoea
when walking on flat ground compared to women without
anxiety (HADS 0e7), whereas the corresponding association
among men was 3.88 (95% CI 1.77e8.50).
In general, having anxiety symptoms increased the
adjusted ORs for reporting dyspnoea within ppFEV1 levels
(Table 4) or COPD stages (Table S3). This trend was most
evident when lung function was measured as ppFEV1.
Compared to women with ppFEV1 100 without anxiety
(HADS 0e7), women with ppFEV1 80e99 without anxiety
had an OR of 2.46 (95% CI 1.25e4.83) for dyspnoea when
walking on flat ground, whereas women with ppFEV1 80e99
with anxiety symptoms (HADS 8e21) had an OR of 7.71 (95%
CI 3.65e16.28) for the same outcome (Table 4). The cor-
responding associations among men were 1.10 (95% CI
0.44e2.73) and 5.17 (95% CI 1.88e14.24), respectively.
Further adjustments for depression did not change the
results (data not shown).Table 3 Weighted prevalence and adjusted odds ratios (ORs) wi
walking on flat ground, dyspnoea when sitting still, and woken a
Women
Dyspnoea
Anxietya Total n (%)b ORc ORd (95% CI)d Ptr
Dyspnoea when walking on flat ground
No anxiety 16,286 632 (3.9) 1.00 1.00 Reference
Borderline 2443 222 (9.1) 2.49 2.27 (1.32 to 3.93)
Anxiety 1299 176 (13.5) 4.10 3.39 (1.95 to 5.88) <0.
Dyspnoea when sitting still
No anxiety 16,286 176 (1.1) 1.00 1.00 Reference
Borderline 2443 60 (2.5) 2.19 2.00 (0.94 to 4.23)
Anxiety 1299 85 (6.5) 6.12 4.86 (2.23 to 10.59) <0.
Woken at night by dyspnoea
No anxiety 22,176 755 (3.4) 1.00 1.00 Reference
Borderline 3160 240 (7.6) 2.38 2.11 (1.30 to 3.43)
Anxiety 1672 148 (8.9) 2.73 2.40 (1.49 to 3.86) <0.
a Anxiety measured by the Hospital Anxiety and Depression Scale (
anxiety Z HADS 11e21.
b Percentage reporting symptom within each anxiety level.
c Adjusted for age (<40.0, 40.0e49.9,., 80.0 years).
d Adjusted for age (<40.0, 40.0e49.9,., 80.0 years), ppFEV1 (10
18.5e24.9, 25.0e29.9, 30.0 kg/m2), smoking history (never smoker,
years, current smoker and <15 pack-years, current smoker and 15 p
unknown), and physical activity (inactive, light activity <1 h per week
vigorous activity, unknown).Sensitivity analyses
In general, the results from the analyses restricted to the
random sample were comparable to the results from the
weighted analyses of the total sample (Tables S4eS6).
However, the estimates were imprecise due to few partic-
ipants in the random sample.
Discussion
In this cross-sectional study from a general population, we
found lung function and anxiety to be independently asso-
ciated with dyspnoea when walking on flat ground, dysp-
noea when sitting still, and woken at night by dyspnoea.
Within lung function levels, reporting dyspnoea was more
common among people with anxiety symptoms than among
people without.
Lung function in association with dyspnoea
Another cross-sectional study from the general population
has also found an association between airflow limitation
and dyspnoea.30 In-line with this, dyspnoea has been found
to discriminate between people with and without bronchial
obstruction.31
The association between lung function and dyspnoea in
people with asthma and COPD is not consistent. Weak
correlations have been found between FEV1 and asthma
symptoms in asthma patients in general practice,12 and
between FEV1 and dyspnoea in patients with COPD.
8 On theth 95% confidence intervals (CIs) for reporting dyspnoea when
t night by dyspnoea according to levels of anxiety.
Men
Dyspnoea
end
d Total n (%)b ORc ORd (95% CI)d Ptrend
d
Dyspnoea when walking on flat ground
15,432 597 (3.9) 1.00 1.00 Reference
1100 102 (9.3) 3.46 4.00 (1.93 to 8.27)
001 565 65 (11.5) 4.50 3.88 (1.77 to 8.50) <0.001
Dyspnoea when sitting still
15,432 206 (1.3) 1.00 1.00 Reference
1100 35 (3.2) 2.85 2.75 (1.57 to 4.82)
001 565 26 (4.6) 4.08 3.64 (2.05 to 6.47) <0.001
Woken at night by dyspnoea
20,493 786 (3.8) 1.00 1.00 Reference
1604 101 (6.3) 1.79 1.70 (1.19 to 2.44)
001 773 66 (8.5) 2.57 2.34 (1.47 to 3.72) <0.001
HADS): No anxiety Z HADS 0e7, borderline Z HADS 8e10, and
0.0, 80.0e99.9, 50.0e79.9, and <50.0), body mass index (<18.5,
former smoker and <15 pack-years, former smoker and 15 pack-
ack-years, unknown), educational level (<10, 10e12, 13 years,
, light activity 1e2 h per week, light activity 3 h per week, only
Table 4 Weighted and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) for reporting dyspnoea when walking n flat ground, dyspnoea when sitting still, and
woken at night by dyspnoea according to joint categories of lung function and anxiety.
Women Men
No anxietya Anxiety symptomsa No anxietya Anxiety symptomsa
Dyspnoea Dyspnoea Dyspnoea Dyspnoea
ppFEV1
b Total n (%)c ORd (95% CI)d Total n (%)c ORd (95% CI)d Total n (%)c ORd (95% CI) Total n (%)d ORd (95% CI)d
Dyspnoea when walking on flat ground Dyspnoea when walking on flat g ound
100 7274 109 (1.5) 1.00 Reference 1428 47 (3.3) 1.99 (0.68 to 5.84) 5936 96 (1.6) 1.00 Referen 604 30 (5.0) 4.46 (0.86 to 23.19)
80e99 6973 284 (4.1) 2.46 (1.25 to 4.83) 1677 205 (12.2) 7.71 (3.65 to 16.28) 7185 158 (2.2) 1.10 (0.44 to .73) 804 66 (8.2) 5.17 (1.88 to 14.24)
<80 2039 239 (11.7) 6.23 (3.45 to 11.28) 637 146 (22.9) 15.14 (7.13 to 32.12) 2311 343 (14.8) 5.75 (2.23 to 4.81) 257 71 (27.6) 15.19 (4.74 to 48.64)
Dyspnoea when sitting still Dyspnoea when sitting still
100 7274 27 (0.4) 1.00 Reference 1428 35 (2.5) 6.08 (1.82 to 20.30) 5936 42 (0.7) 1.00 Referen 604 8 (1.3) 2.11 (0.58 to 7.64)
80e99 6973 97 (1.4) 3.40 (1.68 to 6.87) 1677 52 (3.1) 7.31 (3.28 to 16.29) 7185 72 (1.0) 1.12 (0.37 to .33) 804 30 (3.7) 4.33 (1.50 to 12.47)
<80 2039 52 (2.6) 5.78 (3.05 to 10.97) 637 58 (9.1) 17.81 (6.32 to 50.13) 2311 92 (4.0) 3.30 (1.17 to .30) 257 23 (8.9) 8.92 (2.47 to 32.21)
Woken at night by dyspnoea Woken at night by dyspnoea
100 9734 182 (1.9) 1.00 Reference 1868 112 (6.0) 3.29 (1.59 to 6.78) 7682 170 (2.2) 1.00 Referen 819 27 (3.3) 1.61 (0.81 to 3.20)
80e99 9719 320 (3.3) 1.64 (1.08 to 2.50) 2206 183 (8.3) 4.23 (2.41 to 7.44) 9711 303 (3.1) 1.39 (0.76 to .57) 1196 72 (6.0) 2.79 (1.44 to 5.41)
<80 2723 253 (9.3) 5.33 (3.31 to 8.60) 758 93 (12.3) 6.45 (3.70 to 11.25) 3100 131 (10.1) 5.04 (2.75 to .24) 362 68 (18.8) 9.71 (4.18 to 19.61)
a Anxiety measured by the Hospital Anxiety and Depression Scale (HADS): No anxiety Z HADS 0e7, anxiety symptoms Z HADS 8e2
b ppFEV1 denotes percent predicted forced expiratory volume in one second.
c Percentage reporting symptom within each combined category of lung function and anxiety.
d Adjusted for age (<40.0, 40.0e49.9,.80.0 years), body mass index (<18.5, 18.5e24.9, 25.0e29.9,30.0 kg/m2), smoking history ever smoker, former smoker and <15 pack-years,
former smoker and 15 pack-years, current smoker and <15 pack-years, current smoker and 15 pack-years, unknown), educatio l level (<10, 10e12, 13 years, unknown), and
physical activity (inactive, light activity <1 h per week, light activity 1e2 h per week, light activity 3 h per week, only vigorous ac vity, unknown).
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Lung function, anxiety, and dyspnoea 1155other hand, Schlecht et al.32 found a clear association
between low FEV1 and severe dyspnoea in people with
COPD. These inconsistent findings may be due to the
limited ability of FEV1 to reflect hyperinflation. Hyperin-
flation is one of the main causes of dyspnoea in people with
obstructive lung diseases.8
Dyspnoea may also be a result of abnormalities in respi-
ratory muscles, blood-gases, ventilatory impedance,
breathing patterns, or inability to adapt to heightened
ventilatory demands.9 FEV1 does not necessarily reflect this.Anxiety in association with dyspnoea
A few other studies have used data from the general pop-
ulation when studying the influence of psychological status
on respiratory symptom reporting taking lung function into
account.11,13,16 When studying 600 “healthy” never-
smokers between 14 and 55 years of age without any
respiratory or other major diseases and with normal lung
function, Dales et al.13 found a strong positive association
between anxiety and dyspnoea. This was supported by
Janson et al.16 who also found a clear association between
anxiety and dyspnoea in a cross-sectional epidemiologic
study. In their review from 2005 Chetta et al.15 concluded
that subjects with more psychological symptoms are more
likely to report respiratory symptoms.
Similar associations have also been found among people
with asthma and COPD.10,12 Among patients with asthma in
general practice, anxiety has been found to help explain
symptoms more than lung function and asthma severity.12
Also Giardino et al.10 found an association between
anxiety and shortness of breath after adjusting for lung
function in patients with emphysema.
The cause-and-effect relationships between anxiety and
dyspnoea are unclear.9 Bailey suggests that dyspnoea may
cause anxiety, and anxiety may cause further dyspnoea, and
she refers to this as a dyspnoeaeanxietyedyspnoea cycle.33
However,findings fromaprospectivepopulation-based study
suggest that psychological symptoms like anxiety may cause
dyspnoea.11 In people with COPD, anxiety may cause dysp-
noea by increasing respiratory rate and thereby reducing
expiration time leading to worse hyperinflation.8 Since we
controlled for ppFEV1 in our models, it is unlikely that the
observed association between anxiety and dyspnoea could
be explained by differences in ppFEV1.
Although we found anxiety symptoms to be associated
with reporting dyspnoea in three different situations, the
cause-and-effect relationship between anxiety and dysp-
noea may differ depending on the situation in which dysp-
noea is experienced. One might suspect that anxiety could
cause dyspnoea when sitting still, and that experiencing
dyspnoea when walking on flat ground or waking up with
dyspnoea could cause anxiety. However, the current cross-
sectional study cannot confirm these speculations, and this
needs to be further studied in other study designs.
To distinguish anxiety and depression, which often
coexist,34 we adjusted for depression in separate analyses.
Since this did not change our results, it is unlikely that
depression may explain the observed associations.
Our results indicate that, in addition to lung function,
anxiety may explain some of the variation in reporteddyspnoea. However, whether anxiety causes dyspnoea or
dyspnoea causes anxiety cannot be answered by the
current study. An alternative explanation of our findings
may be that the perception of dyspnoea differs among
those with and without anxiety. Thus, anxiety may affect
the reporting of dyspnoea. Still, when handling patients
with obstructive lung diseases, treatment of both airway
obstruction and anxiety, if present, are important in order
to reduce the total symptom burden.
Methodological considerations
Due to the cross-sectional study design, we cannot draw
conclusions about cause-and-effect relationships.35
However, it is plausible to assume that reduced lung func-
tion or the condition causing it may cause dyspnoea, and
not the other way around. Such assumptions cannot be
drawn about the association between anxiety and dyspnoea
as explained above. Further research on this topic should
therefore be carried out in prospective study designs.
To overcome possible selection bias due to recruitment
of subjects through the symptom or the random sample, we
weighted the participants according to sample origin to
imitate the characteristic properties of all participants in
HUNT 2. Sensitivity analyses restricted to the random
sample were comparable to the results of the weighted
analyses though the small sample size gave imprecise
results. In addition, the prevalence and mean of key vari-
ables in the weighted sample were very close to those in
the random sample.
We studied lung function and anxiety in association with
dyspnoea through the total range of lung function inde-
pendent of possible diagnoses. However, in the supple-
mentary analyses of COPD stages, 30% of people without
COPD may have been misclassified as having COPD due to
the use of pre-bronchodilator measurements.36
Our study is one of fewpopulation-based studies assessing
lung function and anxiety in association with dyspnoea. A
major strength of our study is the large sample size with
awideage span.The response ratewas relatively high. Anon-
responder study did not indicate serious selection bias.37 We
believe our results are valid for the general population of
Norway and other comparable countries.
Conclusion
Impaired lung function and anxiety symptoms were inde-
pendently associated with reporting dyspnoea. Within lung
function levels, reporting dyspnoea was more common
among people with anxiety symptoms than among people
without. This suggests that, in addition to its relation to
reduced lung function, the subjective experience of
breathing discomfort may also influence or be influenced by
anxiety.
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